Readers are directed to Capella for ACC.26 presentations and investor relations contact information for further details.

Zilebesiran is in Phase 3 (ZENITH) cardiovascular outcomes trial, co-developed with Roche, targeting continuous BP control with biannual dosing.

Alnylam announced partnerships with Viz.ai and the American Heart Association to improve early ATTR-CM detection and care coordination via the AWARE study, integrating AI-enabled screening into clinical workflows.

Safety and prescribing information remind that AMVUTTRA (vutrisiran) requires Vitamin A supplementation considerations due to reductions in Vitamin A.

Analyses across baseline diastolic dysfunction grades show higher baseline DDG links to worse outcomes, but vutrisiran associates with lower risk of DDG worsening and favorable NYHA outcomes.

Alnylam presented new data at ACC.26 showing vutrisiran improves health-related quality of life and sustains benefits across ATTR-CM disease stages, including advanced cases and diastolic dysfunction, with real-world data indicating high adherence to quarterly HCP-administered dosing.

A real-world retrospective study reported 93.8% adherence to vutrisiran over roughly 614 days, suggesting strong real-world persistence with the therapy.

At ACC.26, Alnylam highlighted both clinical and real-world findings for its cardiovascular portfolio, including vutrisiran for ATTR-CM and zilebesiran for hypertension, as part of its broader growth narrative.

Financial health indicators show robust growth and margins, though insider selling in the last quarter is noted as a risk factor to monitor.

Safety signals such as hypotension, hyperkalemia, and eGFR decline were generally low and transient across monotherapy and combination therapy cohorts.

Alnylam is a leading RNAi therapeutics company with approved products and partnerships, a market cap near $42 billion, focusing on cardio-metabolic, neuroscience, and hematology programs.

Analysts tracked by InvestingPro show the stock trading slightly above fair value, with several firms maintaining Buy ratings or Equalweight, signaling ongoing institutional interest.